Glaukos Corporation

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to traditional glaucoma treatments, launching its first MIGS device commercially in 2012. Its product portfolio includes the iStent family of micro-scale surgical devices, iDose TR — a first-of-its-kind intracameral procedural pharmaceutical designed to deliver continuous glaucoma drug therapy for up to three years — and Epioxa, the only FDA-approved epithelium-on corneal cross-linking therapy for keratoconus. The company's five core technology platforms span iStent surgical devices, iDose sustained-release procedural pharmaceuticals, iLink bio-activated pharmaceuticals, iLution transdermal pharmaceuticals, and Retina XR bio-erodible sustained-release pharmaceuticals for retinal diseases. Glaukos generates revenue across three main franchises: U.S. Glaucoma, International Glaucoma, and Corneal Health, with the U.S. market representing the majority of sales. The company operates globally and manufactures its products primarily in the United States. Updated Jul 29, 2026